LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Company News/Aurora Spine Fusion System Earns CE Mark
Company News

Aurora Spine Fusion System Earns CE Mark

August 5, 2013 1 min read Premium comments

Advertisement

Aurora Spine Fusion System Earns CE Mark
Zip MIS Interspinous Fusion System / Courtesy: Aurora Spine, Inc.
Secondary

The European Union has granted the CE Mark Approval to Aurora Spine, Inc. for its Zip MIS Interspinous Fusion System allowing it to be sold throughout Europe and in areas of the world that recognize the CE Mark. Aurora Spine officials describe the system as being a posterior, non-pedicle supplemental fixation device that is designed for use in the non-cervical spine. It is intended for plate fixation and attachment to the spinous process to achieve supplemental fusion in the following conditions: degenerative disc disease, spondylolisthesis, trauma and tumor. The Aurora Spine Zip MIS Interspinous Fusion System is intended for use with bone graft material and is not intended for stand-alone use, according to the press release.

“The ZIP MIS Interspinous Fusion System is the first device with the unique ZIP-LOCK technology to provide simple stabilization of the spine for spinal surgery, ” said Laszlo Garamszegi, company chief technology officer. “We are very excited about the CE Mark approval and that now we are able to make this distinctive implant available to patients and surgeons all over Europe.”

Aurora Spine President and CEO Trent Northcutt said, “This is a very significant accomplishment for the company as it moves toward commercialization and its planned launch into the European markets. The CE Mark also paves the way for approvals of the ZIP MIS Interspinous Fusion System device internationally, meeting the company’s global mandate.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy